Literature DB >> 17085305

Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection.

Sanja Vodanovic-Jankovic1, William R Drobyski.   

Abstract

Gammadelta T cells are a unique and minor T-cell subset that differs from conventional alphabeta T cells by virtue of their tissue localization and antigen processing requirements. We have previously shown that ex vivo-activated gammadelta T cells are able to prevent graft rejection without causing clinically significant graft-versus-host disease (GVHD). In the present study, we examined how gammadelta T cells facilitate alloengraftment and to what extent mechanisms used by conventional alphabeta T cells are also used by gammadelta T cells. We observed that, unlike alphabeta T cells, for which CD8(+) T cells are primarily responsible for facilitating engraftment, purified CD8(+)gammadelta(+) T cells administered at the same fractional dose as for the unseparated activated gammadelta T-cell population were insufficient to prevent graft rejection. Furthermore, the ability to prevent graft rejection was not affected by the absence of fully functional fas ligand or perforin cytotoxic pathways, nor was it contingent on the ability of gammadelta T cells to recognize recipient major histocompatibility process alloantigens. Repetitive infusions of a suboptimal dose of gammadelta T cells however were able to rescue mice from graft rejection, suggesting that the persistence of these cells in vivo was critical in facilitating alloengraftment. These studies demonstrate that gammadelta T cells do not use mechanisms used by conventional nontolerant alphabeta T cells to prevent graft rejection. The ability of these cells to promote engraftment without causing GVHD further distinguishes these cells from alphabeta T cells and may be an attribute that can be exploited in the clinical transplantation setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085305      PMCID: PMC1679815          DOI: 10.1016/j.bbmt.2006.08.033

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  52 in total

1.  Qa-1 restricted recognition of foreign antigen by a gamma delta T-cell hybridoma.

Authors:  D Vidović; M Roglić; K McKune; S Guerder; C MacKay; Z Dembić
Journal:  Nature       Date:  1989-08-24       Impact factor: 49.962

2.  Structure and specificity of a class II MHC alloreactive gamma delta T cell receptor heterodimer.

Authors:  L A Matis; A M Fry; R Q Cron; M M Cotterman; R F Dick; J A Bluestone
Journal:  Science       Date:  1989-08-18       Impact factor: 47.728

3.  Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC.

Authors:  S R Sambhara; R G Miller
Journal:  Science       Date:  1991-06-07       Impact factor: 47.728

4.  Recognition of the product of a novel MHC TL region gene (27b) by a mouse gamma delta T cell receptor.

Authors:  K Ito; L Van Kaer; M Bonneville; S Hsu; D B Murphy; S Tonegawa
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

5.  A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2.

Authors:  R D Salter; R J Benjamin; P K Wesley; S E Buxton; T P Garrett; C Clayberger; A M Krensky; A M Norment; D R Littman; P Parham
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

6.  Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity.

Authors:  T Lapidot; I Lubin; A Terenzi; Y Faktorowich; P Erlich; Y Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes.

Authors:  S Porcelli; M B Brenner; J L Greenstein; S P Balk; C Terhorst; P A Bleicher
Journal:  Nature       Date:  1989-10-05       Impact factor: 49.962

8.  An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells.

Authors:  W J Murphy; V Kumar; J C Cope; M Bennett
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

9.  Expression of perforin and serine esterases by human gamma/delta T cells.

Authors:  H Koizumi; C C Liu; L M Zheng; S V Joag; N K Bayne; J Holoshitz; J D Young
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

10.  Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo.

Authors:  M Nakata; M J Smyth; Y Norihisa; A Kawasaki; Y Shinkai; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

Review 2.  Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.

Authors:  Hiroki Torikai; Laurence Jn Cooper
Journal:  Mol Ther       Date:  2016-05-16       Impact factor: 11.454

3.  Deciphering the Contribution of γδ T Cells to Outcomes in Transplantation.

Authors:  Oliver McCallion; Joanna Hester; Fadi Issa
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

4.  Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease.

Authors:  Li Xuan; Xiuli Wu; Yu Zhang; Zhiping Fan; Yiwen Ling; Fen Huang; Fuhua Zhang; Xiao Zhai; Qifa Liu
Journal:  J Transl Med       Date:  2011-12-15       Impact factor: 5.531

5.  T10B9 monoclonal antibody: a short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection.

Authors:  Thomas H Waid; John S Thompson; Maria Siemionow; Stephen A Brown
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.